UROGEN PHARMA ($URGN) posted quarterly earnings results for Q3 2026 on Wednesday, November 4th. The company reported earnings of -$0.03 per share, missing estimates of $0.14 by $0.17. The company also reported revenue of $89,000,000, missing estimates of $91,716,360 by $-2,716,360.
You can see Quiver Quantitative's $URGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UROGEN PHARMA Insider Trading Activity
UROGEN PHARMA insiders have traded $URGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $URGN stock by insiders over the last 6 months:
- MARK SCHOENBERG (Chief Medical Officer) has made 0 purchases and 5 sales selling 86,770 shares for an estimated $3,784,896.
- CHRIS DEGNAN (Chief Financial Officer) sold 2,202 shares for an estimated $80,791
- JASON DREW SMITH (General Counsel) sold 1,519 shares for an estimated $64,618
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
UROGEN PHARMA Hedge Fund Activity
We have seen 108 institutional investors add shares of UROGEN PHARMA stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK removed 2,616,714 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $96,295,075
- PARADIGM BIOCAPITAL ADVISORS LP removed 1,703,949 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $62,705,323
- POINT72 ASSET MANAGEMENT, L.P. added 1,525,549 shares (+inf%) to their portfolio in Q2 2026, for an estimated $56,140,203
- J. GOLDMAN & CO LP removed 726,095 shares (-77.3%) from their portfolio in Q2 2026, for an estimated $26,720,295
- TCG CROSSOVER MANAGEMENT, LLC removed 405,365 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $14,917,431
- SG AMERICAS SECURITIES, LLC added 395,060 shares (+23.8%) to their portfolio in Q2 2026, for an estimated $14,538,207
- BLACKROCK, INC. added 355,894 shares (+12.5%) to their portfolio in Q2 2026, for an estimated $13,096,899
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
UROGEN PHARMA Government Contracts
We have seen $32,844 of award payments to $URGN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ZUSDURI MEDICATION: $32,844
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
